Specialties & Topics
- Arthritis/Rheumatic Disease
- Breast Cancer
- GERD/Peptic Ulcers
An ongoing dialogue on HIV/AIDS, infectious diseases,
September 18th, 2009
Integrase Inhibitors: In Search of an Abbreviation
The alphabet soup that characterizes HIV therapeutics has always been one of its quirky challenges — for example, who could possibly know that 3TC, CBV, TZV, EPZ, and LAM all refer to drugs that are (or contain) lamivudine?
This drives our ID fellows nuts, and is certainly a strong deterrent to non-HIV specialists to learning the field.
(Maybe that’s why they pay us the big bucks… oh wait.)
And while we’ve grown comfortable with the abbreviations for the 3 oldest drug classes — NRTI, NNRTI, and PI — what are we to do with integrase inhibitors? Some candidates:
- “II” — sounds funny when you say it (“eye-eye”), and could be confused with “eleven” depending on the font
- “INSTI” — for “integrase strand transfer inhibitor”; I’ve already seen this one around a lot, but have also seen it written “InSTI” (lower-case n), which is hard to type
- “INI” — for “INtegrase Inhibitor”; same upper vs lower-case issue as “INSTI”, and saying “INI” always has an anatomic (especially umbilical) connotation to it
Still not sure where we’ll end up with this one, but I suspect “INSTI” will rule the day.
Comments are closed.
Paul E. Sax, MD
Learn more about HIV and ID Observations.
- EHR and Drug Prescribing Warnings: The Good, the Bad, the Ugly
- Station Eleven Is a Very Good Read — Even for ID Doctors
- Decision to Lower Price of Pyrimethamine a Good One, Especially Given the Weak Defense of the Price Hike
- WHO Decision to Recommend Treatment for All with HIV an Easy One — Now Comes the Hard Part
- Two Drugs with High Prices — One is (Surprise!) Good Value, The Other is Truly a Rip-off
Subscribe to HIV and ID Observations via Email
Physician's First WatchToday's breaking medical news
- Abacavir AIDS aids clinical care antibiotics antiretroviral therapy ART atazanavir baseball CDC C diff CROI cure darunavir dolutegravir efavirenz elvitegravir etravirine FDA HCV hepatitis C HIV HIV testing ID Learning Unit Infectious Diseases influenza lamivudine lyme disease Massachusetts MRSA Patient Care PEP Policy PrEP prevention primary care raltegravir Research resistance Retrovirus Conference ribavirin rilpivirine ritonavir sofosbuvir TDF/FTC tenofovir